Although we attempted to find effective drugs to overcome Aza resistance in AML with FUS-ERG, AML cells exhibited resistance, even with the addition of 1 μM venetoclax, a BCL2 inhibitor and the first-line drug for AML20 (Fig. 5A). This evidence concerns the gene BCL2 and acute myeloid leukemia.